What is Advanced Cell Diagnostics?
Advanced Cell Diagnostics, Inc. is a leader in developing and commercializing advanced in situ hybridization (ISH) technologies, including its proprietary RNAscope and BaseScope assays. These cutting-edge tools enable precise RNA detection and quantification within individual cells across diverse biological samples. The company's solutions are instrumental in advancing research in critical areas such as oncology, neuroscience, and infectious diseases, facilitating single-cell analysis and multi-omic profiling. Beyond its assay products, Advanced Cell Diagnostics offers comprehensive professional assay services, biomarker assay development, and clinical assay development, supporting biopharmaceutical clients and researchers in accelerating drug development and diagnostic advancements.
How much funding has Advanced Cell Diagnostics raised?
Advanced Cell Diagnostics has raised a total of $40.8M across 4 funding rounds:
Series A
$5.4M
Series B
$12M
Grant
$1.4M
Series C
$22M
Series A (2009): $5.4M with participation from Morningside Venture Investments
Series B (2012): $12M led by New Leaf Venture and Morningside Ventures
Grant (2014): $1.4M supported by National Cancer Institute
Series C (2015): $22M featuring Kenson Ventures, Morningside Ventures, Summit Partners, and New Leaf Venture Partners
Key Investors in Advanced Cell Diagnostics
Kenson Ventures
Kenson Ventures is a venture investment firm based in Palo Alto, California, focusing on providing seed money and strategic advice to startups and companies in the biotechnology and life science sectors. They actively participate in co-investments and often take board seats to support portfolio companies.
Morningside Venture Investments
Morningside Group is a private equity and venture capital firm founded in Hong Kong, managed by investment professionals with deep industry knowledge. They focus on making investments in companies across various sectors, including life sciences.
Summit Partners
Summit Partners is an equity investment firm founded in 1984, headquartered in Boston, Massachusetts, that invests in entrepreneurial companies. Their investment focus spans various industries, supporting growth-stage businesses.
What's next for Advanced Cell Diagnostics?
With a history of consistent capital acquisition, including a significant Series C round in 2015, Advanced Cell Diagnostics is well-positioned for its next phase of growth. The recent strategic investment, following substantial prior financing rounds, indicates strong investor confidence in the company's technological prowess and market strategy. This backing is likely to be deployed towards expanding its product portfolio, enhancing its service offerings, and potentially broadening its global reach. The company's focus on enabling precise RNA analysis for drug development and diagnostics suggests a strategic direction aimed at capturing a larger share of the rapidly evolving biopharma and research tools market.
See full Advanced Cell Diagnostics company page
